On Thursday, Shares of Schlumberger Limited.(NYSE:SLB), lost -2.21% to $90.23.
Cameron (CAM) and OneSubsea®, a Cameron and Schlumberger (SLB) company, have won Spotlight on New Technology Awards at the Offshore Technology Conference (OTC) by meeting the criteria for new, innovative, proven products of broad interest that have noteworthy impact.
Cameron won an award for its Mark IV High Availability (HA) Control System for Blowout Preventers (BPs). Cameron’s Mark IV HA control system is the industry’s first three-POD control system. The new system allows drillers to continue operating when one POD becomes inaccessible. Because of this configuration, the Mark IV HA BOP control system improves operational availability to as much as 98% and reduces the likelihood of a POD-related stack pull by up to 73%. This system builds on the success of the Mark III control system by streamlining the POD design, making it smaller and lighter in addition to increasing functionality.
Schlumberger Limited supplies technology, integrated project management, and information solutions to the oil and gas exploration and production industries worldwide. The company operates through Reservoir Characterization Group, Drilling Group, and Production Group segments.
Shares of Genworth Financial, Inc. (NYSE:GNW), declined -0.96% to $8.25, during its last trading session.
Genworth Financial, will offer a listen-only broadcast of its 2015 Annual Meeting of Stockholders to be held at 9:00 a.m. (ET), May 14, 2015.
Genworth Financial, Inc. provides insurance, retirement, and homeownership solutions in the United States and internationally. It operates through U.S. Life Insurance, International Mortgage Insurance, U.S. Mortgage Insurance, International Protection, and Runoff segments. The U.S. Life Insurance segment offers and manages various life insurance, long-term care insurance, and fixed annuity products.
At the end of Thursday’s trade, Shares of Verisk Analytics, Inc. (NASDAQ:VRSK), lost -0.54% to $72.10.
Verisk Analytics, declared the pricing of an offering of 9,640,000 shares of its Class A common stock at $70.00 per share. The Company has granted the underwriters a 30-day option to purchase up to 964,000 additional shares of the Common Stock. The closing of the offering is predictable to occur on May 12, 2015, subject to satisfaction of customary closing conditions.
BofA Merrill Lynch, Morgan Stanley & Co. LLC, Wells Fargo Securities, LLC, J.P. Morgan Securities LLC and SunTrust Robinson Humphrey, Inc. are acting as joint book-running managers for the offering.
Verisk Analytics, Inc. provides information about risk to professionals in insurance, healthcare, financial services, government, supply chain, and risk administration in the United States and internationally.
Finally, Sequenom Inc. (NASDAQ:SQNM), ended its last trade with -15.21% drop, and closed at $3.79.
Sequenom, stated total revenues of $37.8 million for the first quarter of 2015, an enhance of 2% contrast to revenues of $37.1 million for the first quarter of 2014.
Net earnings improved to $14.3 million, or $0.12 per share, basic and $0.11 per share, diluted, for the first quarter, as contrast to a net loss of $15.7 million, or $0.13 per share, basic and diluted, for the first quarter of 2014. The improvement in the net earnings from the preceding year is due to a $21.0 million gain on the pooled patents agreement with Illumina, Inc., in addition to improved gross margins and reduced operating expenses contrast to the preceding year first quarter.
Total cost of revenues reduced to $19.3 million for the first quarter of 2015, contrast to $22.8 million for the preceding year quarter. The decrease was primarily due to continued cost improvements to Sequenom Laboratories’ existing tests offset by the impact of higher test volumes.
Gross margin for the first quarter of 2015 was 49% as contrast to gross margin of 39% for the first quarter of 2014. This improvement is attributable primarily to the enhance in collections for tests performed in the current and preceding quarters, the enhance in the volume of tests on accrual accounting and improved cost efficiencies in processing patient samples.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
